In the study of Yap et al., a change in the mutant variant profile from BRAF V600E to V600K was detected in extracellular vesicles from a MEL patient under BRAF-MEK inhibition, and the emergence of KRAS G12D mutation was found after cetuximab treatment of a CRC patient with a KRAS wildtype primary tumor [47]. Here, MAP2K7 is linked to melorheostosis.